Cited by 658Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Open access

Green, Robert C.·2009·JAMA

DOI 10.1001/jama.2009.1866PMC PMC2902875

Open this paper in CoChat — free account

Abstract

CONTEXT: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial. OBJECTIVE: To determine the efficacy, safety, and tolerability of tarenflurbil. DESIGN, SETTING, AND PATIENTS: A multicenter, randomized, double-blind, placebo-controlled trial enrolling patients with mild AD was conducted at 133 trial sites in the United States between February 21, 2005, and April 30, 2008. Concomitant treatment with cholinesterase inhibitors or memantine was permitted. INTERVENTION: Tarenflurbil, 800 mg, or placebo, administered twice a day. MAIN OUTCOME MEASURES: Co-primary efficacy end points were the change from baseline to month 18 in total score on the subscale of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog, 80-point version) and Alzheimer Disease Cooperative Studies-activities of daily living (ADCS-ADL) scale. Additional prespecified slope analyses explored the possibility of disease modification. RESULTS: Of the 1684 participants randomized, 1649 were included in the analysis, and 1046 completed the trial. Tarenflurbil had no beneficial effect on the co-primary outcomes (difference in change from baseline to month 18 vs placebo, based on least squares means: 0.1 for ADAS-Cog; 95% CI, -0.9 to 1.1; P = .86 and -0.5 for ADCS-ADL; 95% CI, -1.9 to 0.9; P = .48) using an intent-to-treat analysis. No significant differences occurred in the secondary outcomes. The ADAS-Cog score decreased by 7.1 points over 18 months. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. CONCLUSION: Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00105547.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2009.1866

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients].
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,010
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,851
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,006
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175

Show all 44 references

Sorted by citations

Items 301–400 of 658

Ellagic Acid: A Green Multi-Target Weapon That Reduces Oxidative Stress and Inflammation to Prevent and Improve the Condition of Alzheimer’s Disease
Alfei, S., & Zuccari, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020844 · Cited by 28
Therapeutic modulation of neurogenesis to improve hippocampal plasticity and cognition in aging and Alzheimer's disease
MOSTAFA, M., Disouky, A., & Lazarov, O. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00580 · Cited by 31
Intramembrane proteolysis within lysosomes
Schröder, B., & Säftig, P. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.012 · Cited by 28
Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer’s mice
Li, S., Hou, H., Mori, T., Sawmiller, D. R., Smith, A., Tian, J., Wang, Y., Giunta, B. N., Sanberg, P. R., Zhang, S., et al. (2015) · Scientific Reports · doi:10.1038/srep11322 · Cited by 28
γ‐Secretase modulators do not induce Aβ‐rebound and accumulation of β‐C‐terminal fragment
Li, T., Huang, Y., Jin, S., Ye, L., Rong, N., Yang, X., Ding, Y., Cheng, Z., Zhang, J., Wan, Z., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07560.x · Cited by 28
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
Wattmo, C., Wallin, Å. K., & Minthon, L. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-134 · Cited by 28
Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease
Lenz, R. A., Pritchett, Y., Berry, S. M., Llano, D. A., Han, S., Berry, D. A., Sadowsky, C., Abi‐Saab, W., & Saltarelli, M. D. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000093 · Cited by 31
Alzheimer's disease drug development: translational neuroscience strategies
Cummings, J. L., Banks, S. J., Gary, R. K., Kinney, J. W., Lombardo, J. M., Walsh, R. R., & Zhong, K. (2013) · CNS Spectrums · doi:10.1017/s1092852913000023 · Cited by 27
Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease
Stopschinski, B. E., Weideman, R. A., McMahan, D., Jacob, D. A., Little, B. B., Chiang, H.-S., Saez Calveras, N., & Stuve, O. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231156674 · Cited by 26
New and emerging treatments for Alzheimer's disease
Corbett, A., & Ballard, C. G. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.675327 · Cited by 27
Sample size determination in group‐sequential clinical trials with two co‐primary endpoints
Asakura, K., Hamasaki, T., Sugimoto, T., Hayashi, K., Evans, S. R., & Sozu, T. (2014) · Statistics in Medicine · doi:10.1002/sim.6154 · Cited by 26
Modulation of Gamma-Secretase for the Treatment of Alzheimer's Disease
Tate, B. A., McKee, T. D., Loureiro, R. M. B., Dumin, J. A., Xia, W., Pojasek, K., Austin, W., Fuller, N. O., Hubbs, J. L., Shen, R., et al. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/210756 · Cited by 26
Exploring the chemical space of γ-secretase modulators
Zettl, H., Weggen, S., Schneider, P., & Schneider, G. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.05.007 · Cited by 26
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Sui, D., Liu, M., & Kuo, M. (2015) · Journal of Visualized Experiments · doi:10.3791/51537 · Cited by 28
The use of non-steroidal anti-inflammatory drugs in neurological diseases
Terzi, M., Altun, G., Şen, S., Kocaman, A., Kaplan, A. A., Yurt, K. K., & Kaplan, S. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.03.003 · Cited by 26
Constipation in Tg2576 mice model for Alzheimer’s disease associated with dysregulation of mechanism involving the mAChR signaling pathway and ER stress response
Kim, J. E., Park, J. J., Lee, M. R., Choi, J. Y., Song, B., Park, J. W., Kang, M. J., Son, H. J., Hong, J. T., & Hwang, D. Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215205 · Cited by 26
Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives
Sun, B., Chen, Y., Fan, D., Zhu, C., Zeng, F., & Wang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1810-y · Cited by 27
Morus alba fruit diet ameliorates cognitive deficit in mouse model of streptozotocin-induced memory impairment
Sood, P., Singh, V., & Shri, R. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01199-2 · Cited by 25
Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report
Korn, E. L., & Freidlin, B. (2011) · The American Journal of Bioethics · doi:10.1080/15265161.2010.546471 · Cited by 25
A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease
Geerts, H., Roberts, P., Spiros, Ä., & Carr, R. A. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00047 · Cited by 25
Discovery of 4′-OH-flurbiprofen Mannich base derivatives as potential Alzheimer’s disease treatment with multiple inhibitory activities
Liu, H., Qiang, X., Song, Q., Li, W., He, Y., Ye, C., Tan, Z., & Deng, Y. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.040 · Cited by 25
Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies
Dileep, K. V., & Chandra, R. (2019) · Current Drug Targets · doi:10.2174/1389450120666190806153206 · Cited by 26
Common Factors of Alzheimer’s Disease and Rheumatoid Arthritis—Pathomechanism and Treatment
Trzeciak, P., Herbet, M., & Dudka, J. (2021) · Molecules · doi:10.3390/molecules26196038 · Cited by 24
DOTA: Deep Learning Optimal Transport Approach to Advance Drug Repositioning for Alzheimer’s Disease
Chyr, J., Gong, H., & Zhou, X. (2022) · Biomolecules · doi:10.3390/biom12020196 · Cited by 24
Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study
Shahroz, M. M., Sharma, H. K., Altamimi, A. S. A., Alamri, M. A., Ali, A., Ali, A., Alqahtani, S. M., Altharawi, A., Alabbas, A. B., Alossaimi, M. A., et al. (2022) · Molecules · doi:10.3390/molecules27041159 · Cited by 24
Effect of Donepezil in Alzheimer Disease Can Be Measured by a Computerized Human Analog of the Morris Water Maze
Hort, J., Andel, R., Mokrišová, I., Gažová, I., Amlerová, J., Vališ, M., Coulson, E. J., Harrison, J., Windisch, M., & Laczó, J. (2013) · Neurodegenerative Diseases · doi:10.1159/000355517 · Cited by 24
-Secretase Modulators: Can We Combine Potency with Safety?
Gijsen, H. J. M., & Mercken, M. H. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/295207 · Cited by 24
Preventing Alzheimer's disease by means of natural selection
Demetrius, L., & Driver, J. A. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0919 · Cited by 24
Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain
Ludwig, J., Höffle‐Maas, A., Samochocki, M., Luttmann, E., Albuquerque, E. X., Fels, G., & Maelicke, A. (2010) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2010.505239 · Cited by 24
Initial Optimization of a New Series of γ-Secretase Modulators Derived from a Triterpene Glycoside
Fuller, N. O., Hubbs, J. L., Austin, W., Creaser, S. P., McKee, T. D., Loureiro, R. M. B., Tate, B. A., Xia, W., Ives, J. L., Findeis, M. A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300256p · Cited by 23
The Role of Microglia in the Etiology and Evolution of Chronic Traumatic Encephalopathy
Makinde, H. M., Just, T. B., Cuda, C. M., Perlman, H., & Schwulst, S. J. (2017) · Shock · doi:10.1097/shk.0000000000000859 · Cited by 24
Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
Dar, K. B., Bhat, A. H., Amin, S., Reshi, B. A., Zargar, M. A., Masood, A., & Ganie, S. A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00741-0 · Cited by 23
Modulation of γ-Secretase Activity by a Carborane-Based Flurbiprofen Analogue
Saretz, S., Basset, G., Useini, L., Laube, M., Pietzsch, J., Drača, D., Maksimović‐Ivanić, D., Trambauer, J., Steiner, H., & Hey‐Hawkins, E. (2021) · Molecules · doi:10.3390/molecules26102843 · Cited by 23
Challenges in Designing Therapeutic Agents for Treating Alzheimer’s Disease-from Serendipity to Rationality
Rashid, U., & Ansari, F. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50002-7 · Cited by 23
Preventing cognitive decline in older African Americans with mild cognitive impairment: Design and methods of a randomized clinical trial
Rovner, B. W., Casten, R. J., Hegel, M. T., & Leiby, B. E. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.02.016 · Cited by 22
DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells
Xiang, J. Y., Zhang, W., Cai, X., Cai, M., Yu, Z., Yang, F., Zhu, W., Li, X., Wu, T., Zhang, J.-S., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.025 · Cited by 23
Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer’s Disease
Nelson, A. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.858429 · Cited by 24
Protein structures in Alzheimer's disease: The basis for rationale therapeutic design
Montoliu‐Gaya, L., & Villegas, S. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.10.005 · Cited by 24
Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease
Han, S.-H., & Mook‐Jung, I. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.7.893 · Cited by 23
Potential Use of γ-Secretase Modulators in the Treatment of Alzheimer Disease
Wagner, S. L., Tanzi, R. E., Mobley, W. C., & Galasko, D. R. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.540 · Cited by 22
Development of the Daily Living Questionnaire (DLQ): A Factor Analysis Study
Rosenblum, S., Josman, N., & Toglia, J. P. (2017) · The Open Journal of Occupational Therapy · doi:10.15453/2168-6408.1326 · Cited by 24
Alzheimer's Disease
Mandell, A. M., & Green, R. C. (2011) · Wiley eBooks · doi:10.1002/9781444344110.ch1 · Cited by 22
Self-citation
Failure After Failure. What Next in AD Drug Development?
Aisen, P. S. S. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.23 · Cited by 21
A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study
Al-azzawi, S., Masheta, D., Guildford, A. L., Phillips, G. J., & Santin, M. (2020) · Nanomaterials · doi:10.3390/nano10081590 · Cited by 21
The next step of neurogenesis in the context of Alzheimer’s disease
Moradi, H. R., Hajali, V., Khaksar, Z., Vafaee, F., Forouzanfar, F., & Negah, S. S. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06520-9 · Cited by 20
Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease
Aquino, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694329 · Cited by 20
Combination treatments in Alzheimer’s disease: risks and benefits
Sobów, T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.43 · Cited by 20
Can novel therapeutics halt the amyloid cascade?
Prins, N. D., Visser, P. J., & Scheltens, P. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt28 · Cited by 20
Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers
Marizzoni, M., Ferrari, C., Jovicich, J., Albani, D., Babiloni, C., Cavaliere, L., Didic, M., Forloni, G., Galluzzi, S., Hoffmann, K., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180152 · Cited by 20
Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease
Bu, X., Jiao, S., Lian, Y., & Wang, Y. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151215110114 · Cited by 20
AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials
Vellas, B. J., Pesce, A., Robert, P. H., Aisen, P. S. S., Ancoli‐Israel, S., Andrieu, S., Cedarbaum, J. M., Dubois, B., Siemers, E., Spire, J., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.2020 · Cited by 20
Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects
Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 19
Potential Therapeutic Implications of Gelsolin in Alzheimer's Disease
Ji, L., Zhao, X., & Hua, Z. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141548 · Cited by 20
Treatment of Alzheimer’s Disease: Current Management and Experimental Therapeutics
Honig, L. S., & Boyd, C. D. (2013) · Current Translational Geriatrics and Experimental Gerontology Reports · doi:10.1007/s13670-013-0056-3 · Cited by 19
Latest advances on interventions that may prevent, delay or ameliorate dementia
Wilson, D., Peters, R. K., Ritchie, K. A., & Ritchie, C. W. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310397636 · Cited by 20
LW-AFC, a new formula from the traditional Chinese medicine Liuwei Dihuang decoction, as a promising therapy for Alzheimer's disease: Pharmacological effects and mechanisms
Cheng, X., Huang, Y. Y., Zhang, Y., & Zhou, W. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.10.005 · Cited by 19
Detection and modulation of neurodegenerative processes using graphene-based nanomaterials: Nanoarchitectonics and applications
Tiwari, P., & Tiwari, S. (2022) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2022.102824 · Cited by 19
Lipase-catalyzed alcoholytic resolution of (R,S)-flurbiprofenyl azolides for preparation of (R)-NO-flurbiprofen ester prodrugs
Ciou, J., Wang, P., Wu, A., & Tsai, S. (2011) · Process Biochemistry · doi:10.1016/j.procbio.2011.01.017 · Cited by 19
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions
Loeffler, D. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00459 · Cited by 20
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 18
Nose to brain delivery of flurbiprofen from a solid lipid nanoparticles-based thermosensitive in-situ gel.
Choudhary, A. J., Mahajan, S., & Majumdar, A. S. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104062 · Cited by 18
Modulating Metals As A Therapeutic Strategy For Alzheimer’s Disease
Hung, L. W., & Barnham, K. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.32 · Cited by 18
Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints
Asakura, K., Hamasaki, T., & Evans, S. R. (2016) · Biometrical Journal · doi:10.1002/bimj.201600026 · Cited by 18
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 18
Longitudinal decline in mild‐to‐moderate Alzheimer's disease: Analyses of placebo data from clinical trials
Thomas, R. G., Albert, M., Petersen, R. C., & Aisen, P. S. S. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.002 · Cited by 18
Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model
Reinitz, F., Chen, E. Y., Nicolis di Robilant, B., Chuluun, B., Antony, J., Jones, R. C., Gubbi, N., Lee, K., Ho, W. H. D., Kolluru, S. S., et al. (2022) · eLife · doi:10.7554/elife.66037 · Cited by 18
Tarenflurbil
Sano, M. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.94 · Cited by 17
Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Shirbhate, E., Patel, V. K., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220907114443 · Cited by 18
Application of CRISPR/Cas9 System in the Treatment of Alzheimer’s Disease and Neurodegenerative Diseases
Rahimi, A., Sameei, P., Mousavi, S., Ghaderi, K., Hassani, A., Hassani, S., & Alipour, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04143-2 · Cited by 18
A review of the roles of pathogens in Alzheimer’s disease
Zhao, M., Wang, Y., Shen, Y., Wei, C., Zhang, G., & Sun, L. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1439055 · Cited by 18
Comprehensive investigation of multiple targets in the development of newer drugs for the Alzheimer's disease
Ashwini, P., Bodhankar, S. L., Muthal, A., Kumar, D., Pawar, A., & Kulkarni, R. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.016 · Cited by 19
Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT
Howard, R. J., Zubko, O., Gray, R. G., Bradley, R., Harper, E., Kelly, L. J., Pank, L., O'Brien, J. T., Fox, C., Tabet, N., et al. (2020) · Efficacy and Mechanism Evaluation · doi:10.3310/eme07020 · Cited by 17
NSAIDs may protect against age-related brain atrophy
Bendlin, B. B. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00035 · Cited by 17
The need for thorough phase II studies in medicines development for Alzheimer’s disease
Gray, J. A., Fleet, D., & Winblad, B. G. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0153-y · Cited by 17
Current status of vaccination therapies in Alzheimer's disease
Karran, E. H. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12009 · Cited by 16
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Niazi, S. K., Mariam, Z., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126683 · Cited by 16
Tarenflurbil for Alzheimer's disease: a “shot on goal” that missed
Vellas, B. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70030-2 · Cited by 16
Adverse events and dropouts in Alzheimer's disease studies: What can we learn?
Henley, D. B., Sundell, K. L., Sethuraman, G., & Schneider, L. S. S. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.11.008 · Cited by 17
Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer’s Disease
Brod, S. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215125 · Cited by 16
Alzheimer's disease clinical trials: past failures and future opportunities
Yaari, R., & Hake, A. M. (2015) · Clinical Investigation · doi:10.4155/cli.14.127 · Cited by 16
Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans
Ling, I., Golde, T. E., Galasko, D. R., & Koo, E. H. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0137-y · Cited by 16
General practitioner use of a C-reactive protein point-of-care test to help target antibiotic prescribing in patients with acute exacerbations of chronic obstructive pulmonary disease (the PACE study): study protocol for a randomised controlled trial
Bates, J., Francis, N. A., White, P. T., Gillespie, D., Thomas‐Jones, E., Breen, R., Kirby, N., Hood, K., Gal, M., Phillips, R., et al. (2017) · Trials · doi:10.1186/s13063-017-2144-8 · Cited by 16
Efficient four‐drug cocktail therapy targeting amyloid‐β peptide for Alzheimer's disease
Asai, M., Iwata, N., Tomita, T., Iwatsubo, T., Ishiura, S., Saido, T. C., & Maruyama, K. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22503 · Cited by 15
Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead
Dai, Y., Lei, C., Zhang, Z., Qi, Y., Lao, K., & Gou, X. (2022) · Current Drug Targets · doi:10.2174/1389450123666220421124030 · Cited by 15
New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Chen, H., Xu, J., Xu, H., Luo, T., Li, Y., Jiang, K., Shentu, Y., & Tong, Z. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041133 · Cited by 15
Should development of Alzheimer¿s disease-specific intravenous immunoglobulin be considered?
Loeffler, D. A. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0198-z · Cited by 15
Emerging amyloid and tau targeting treatments for Alzheimer’s disease
Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326819 · Cited by 16
Evaluating the Impact of Music & Memory’s Personalized Music and Tablet Engagement Program in Wisconsin Assisted Living Communities: Pilot Study
Ford, J. H., Dodds, D., Hyland, J., & Potteiger, M. (2019) · JMIR Aging · doi:10.2196/11599 · Cited by 16
BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease
Scannevin, R. H., Chollate, S., Brennan, M. S., Snodgrass-Belt, P., Peng, H., Xu, L. S., Jung, M., Bussière, T., Arastu, M. F., Talreja, T., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.006 · Cited by 15
Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer’s disease and related dementias
Hennekens, C. H., Bensadon, B. A., Zivin, R. A., & Gaziano, J. M. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1088784 · Cited by 15
Testing the amyloid hypothesis of Alzheimer's disease in vivo
Gandy, S. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70055-7 · Cited by 15
Gene therapy: an alternative to treat Alzheimer’s disease
Doshi, V., Joshi, G., Sharma, S., & Choudhary, D. K. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02873-z · Cited by 14
Emerging paradigms in Alzheimer's therapy
Agnes Preethy, H., Rajendran, K., Sukumar, A. J., & Krishnan, U. M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176872 · Cited by 15
Deep brain stimulation targeting the fornix for mild Alzheimer dementia: design of the ADvance randomized controlled trial
Lyketsos, C. G., Holroyd, K., Fosdick, L., Smith, G. S., Leoutsakos, J., Munro, C. A., Oh, E. S., Drake, K. E., Rosenberg, P., Anderson, W. S., et al. (2015) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s81542 · Cited by 15
Treatment effects in multiple cognitive domains in Alzheimer’s disease: a two-year cohort study
Behl, P., Edwards, J. D., Kiss, A., Lanctôt, K. L., Streiner, D. L., Black, S. E., & Stuss, D. T. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt280 · Cited by 15
Mitochondria-Microbiota Interaction in Neurodegeneration
Krämer, P. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.776936 · Cited by 14
The role of brain-derived neurotrophic factor and the neurotrophin receptor p75NTR in age-related brain atrophy and the transition to Alzheimer’s disease
Cade, S., Zhou, X., & Bobrovskaya, L. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0111 · Cited by 14
Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo
Jeong, J., Han, M., Jeon, S., Kim, Y., Choi, H. J., Choi, W., Kwon, K., Choi, J.-R., & Lee, E.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-02412-1 · Cited by 13
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
Plasma Exchange in Alzheimer's Disease
Rohrer, L., Yünce, M., Montine, T. J., & Shan, H. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.09.005 · Cited by 14

Authors: Green, R. C.
Affiliations: Boston University (US)
Corresponding author: Green, Robert C.
ORCID: Green, Robert C.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2009-12-16
Volume: 302
Issue: 23
Pages: 2557
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2009.1866
PMC: PMC2902875
OpenAlex: W1982816514
Cited by: 643
References: 44
Citations by year: 2026: 11 · 2025: 25 · 2024: 39 · 2023: 22 · 2022: 28 · 2021: 32 · 2020: 43 · 2019: 32 · 2018: 26 · 2017: 40 · 2016: 40 · 2015: 31 · 2014: 44 · 2013: 52 · 2012: 63
FWCI: 38.79
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: University of Pennsylvania
National Institute for Health and Care Research
National Institutes of Health (RR00533, HG02213, AG13846)
National Institute on Aging (P30AG008051, K24AG027841, P50AG005142, P30AG013846, P30-AG13846))
National Human Genome Research Institute (R01HG002213, R01 HG02213)
National Center for Research Resources (M01-RR-00533, M01RR000533)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, mild Alzheimer disease, cognitive decline, activities of daily living, disease modification, ADAS-Cog, drug safety and efficacy, dizziness, anemia, infection
MeSH terms: Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Cognition Disorders, Double-Blind Method, Enzyme Inhibitors, Female, Flurbiprofen, Humans, Male, Middle Aged, Peptide Fragments, Amyloid beta-Peptides, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks